{
    "ticker": "MDNAF",
    "name": "Medicenna Therapeutics Corp.",
    "description": "Medicenna Therapeutics Corp. is a clinical-stage biotechnology company focused on the development of novel targeted therapies for the treatment of cancer. Founded in 2015, the company is headquartered in Toronto, Canada, and is committed to advancing innovative therapies based on its proprietary platform technology. Medicenna's lead product candidate, MDNA55, is an engineered interleukin-4 (IL-4) that aims to selectively target and destroy cancer cells while sparing healthy tissues, offering a promising treatment option for patients with recurrent glioblastoma and other cancers. The company is also developing additional pipeline candidates that leverage its expertise in immunotherapy and the tumor microenvironment. Medicenna's mission revolves around improving the lives of patients through the development of its promising therapeutic candidates that harness the body's immune system in the fight against cancer. The company is dedicated to advancing its clinical trials and is actively engaged in partnerships and collaborations to enhance its research and development efforts. Medicenna is focused on providing hope to patients with limited treatment options by delivering therapies that are not only effective but also have improved safety profiles compared to traditional therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Toronto, Ontario, Canada",
    "founded": "2015",
    "website": "https://www.medicenna.com",
    "ceo": "Dr. Fahar Merchant",
    "social_media": {
        "twitter": "https://twitter.com/Medicenna",
        "linkedin": "https://www.linkedin.com/company/medicenna-therapeutics/"
    },
    "investor_relations": "https://investors.medicenna.com",
    "key_executives": [
        {
            "name": "Dr. Fahar Merchant",
            "position": "CEO"
        },
        {
            "name": "Dr. John D. P. K. Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "MDNA55",
                "MDNA11"
            ]
        }
    ],
    "seo": {
        "meta_title": "Medicenna Therapeutics Corp. | Targeted Cancer Therapies",
        "meta_description": "Explore Medicenna Therapeutics Corp., a biotechnology company focused on developing targeted therapies for cancer treatment. Learn about their innovative approaches and clinical developments.",
        "keywords": [
            "Medicenna",
            "Biotechnology",
            "Cancer Treatment",
            "IL-4 Therapy",
            "Targeted Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Medicenna Therapeutics focus on?",
            "answer": "Medicenna Therapeutics focuses on developing targeted therapies for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of Medicenna?",
            "answer": "Dr. Fahar Merchant is the CEO of Medicenna Therapeutics Corp."
        },
        {
            "question": "Where is Medicenna headquartered?",
            "answer": "Medicenna is headquartered in Toronto, Ontario, Canada."
        },
        {
            "question": "What is Medicenna's lead product candidate?",
            "answer": "Medicenna's lead product candidate is MDNA55, an engineered IL-4 therapy for recurrent glioblastoma."
        },
        {
            "question": "When was Medicenna founded?",
            "answer": "Medicenna was founded in 2015."
        }
    ],
    "competitors": [
        "AVEO",
        "CLVS",
        "FGEN",
        "IMMP"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "CELG"
    ]
}